Clinical Trials on Carcinoma, Non-Small-Cell Lung in Russian Federation

Total 481 results

Autonomous Non-Profit Organization National Society...

Recruiting

Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"

Stage III Non-small Cell Lung Cancer

Russian Federation
Hoffmann-La Roche

Completed

A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Russian Federation
N.N. Blokhin National Medical Research Center of...

Recruiting

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy (TRUST)

Non Small Cell Lung Cancer | EGFR Gene Mutation | T790M

Russian Federation
Biocad

Active, not recruiting

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

Melanoma | Non Small Cell Lung Cancer

Russian Federation
Celgene

Completed

An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin

Non-Small Cell Lung Cancer (NSCLC)

Russian Federation
Biocad

Unknown

Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS) (DOMINUS)

Non Small Cell Lung Cancer Stage IIIB | Non-Small Cell Carcinoma of Lung, TNM Stage 4

Russian Federation, Belarus
Spectrum Pharmaceuticals, Inc

Withdrawn

A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Carcinoma

United States, Russian Federation
AstraZeneca

Active, not recruiting

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy (LOTOS)

Advanced or Metastatic NSCLC

Russian Federation
Achieve Life Sciences

Completed

Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Russian Federation
AstraZeneca

Recruiting

Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations

Non-small-cell Lung Cancer

Russian Federation
NewVac LLC
Janssen Pharmaceutica N.V., Belgium

Completed

Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Epithelial Ovarian Cancer | Non-small Cell Lung Cancer

Russian Federation
UCB Pharma

Completed

A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer

Carcinoma | Non-Squamous Non-Small-Cell Lung Cancer

Poland, Russian Federation, Hungary
AstraZeneca

Recruiting

A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia (NIS durvalumab)

NSCLC, Non-small-cell Lung Carcinoma

Russian Federation
Catalysis SL

Completed

Oncoxin® and Quality of Life in Cancer Patients

Non-small Cell Lung Cancer Stage III | Gastric Cancer Stage III | Gastric Cancer Stage II | Non-small Cell Lung Cancer Stage II

Kazakhstan, Russian Federation
Ascenta Therapeutics

Completed

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Russian Federation, United States, Ukraine
Eli Lilly and Company

Completed

Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy

Carcinoma, Non-Small-Cell Lung

Russian Federation
AstraZeneca

Completed

An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer). (ORTUS)

Non-Small Cell Lung Cancer

Russian Federation
BIND Therapeutics

Completed

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Russian Federation
Eli Lilly and Company

Withdrawn

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Metastatic Squamous Non-Small Cell Lung Cancer | Locally Advanced Squamous Non-Small Cell Lung Cancer

Italy, Romania, Germany, Belgium, Russian Federation, United States, United Kingdom
Mabscale, LLC

Recruiting

A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Russian Federation
Novartis Pharmaceuticals

Completed

Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

Non Small Cell Lung Cancer

France, Canada, United States, Russian Federation, Denmark
Hoffmann-La Roche

Completed

A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC) (MERIT)

Non-Squamous Non-Small Cell Lung Cancer

Hong Kong, Spain, Russian Federation, France, Bulgaria, Germany, Estonia, Italy, Poland, Taiwan, United Kingdom, Singapore, Ireland, Belgium
AstraZeneca

Recruiting

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC in Routine Practices in Russia (PASSAT)

Unresectable /Inoperable Locally Advanced (Stage II-III) Non-small Cells Lung Cancer (NSCLC)

Russian Federation
Checkpoint Therapeutics, Inc.

Terminated

Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (CONTERNO)

Metastatic Non-squamous Non Small Cell Lung Cancer

Peru, Russian Federation, South Africa, New Zealand, Georgia, Thailand, Brazil, Malaysia
Active Biotech AB

Completed

ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Denmark, Russian Federation
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Nonsmall Cell Lung Cancer | Carcinoma，Non-Small-Cell Lung | Non-small-cell Lung Carcinoma | Lung Carcinomas, Non-Small-Cell

Spain, Australia, Belarus, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Georgia, Greece, Hungary, Jordan, Lebanon, Malaysia, Mexico, Philippines, Poland, Romania, Russian Federation, Taiwan, Thailand, Turkey, Ukraine
Axelar AB

Completed

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

Non-small-cell Lung Cancer | Squamous Cell Carcinoma | Adenocarcinoma of the Lung

Russian Federation, Ukraine, Belarus, Hungary, Poland
Biocad

Completed

A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Ukraine, Belarus, India, Russian Federation
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel (NSCLC)

Non-small Cell Lung Cancer

United States, Hungary, Poland, Russian Federation
BIND Therapeutics

Completed

A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer

Squamous Cell Non-small Cell Lung Cancer | KRAS Positive Patients With Non-small Cell Lung Cancer

United States, Russian Federation
Bristol-Myers Squibb

Completed

Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer (CheckMate 078)

Non-Small Cell Lung Cancer

China, Hong Kong, Russian Federation, Singapore
AstraZeneca

Completed

Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (DUART)

Non-small Cell Lung Cancer

Italy, Poland, France, Spain, United States, Russian Federation
Kidney Cancer Research Bureau

Unknown

Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.

Non-small Cell Lung Cancer Metastatic | Pleural Effusion, Malignant | Renal Cell Cancer Metastatic

Russian Federation
AstraZeneca

Completed

Epidemiological Study to Describe Non Small Cell Lung Cancer (NSCLC) Clinical Management Patterns in Central Eastern Europe and Russia (Lung-EPICLIN) (EPICLIN)

Non Small Cell Lung Cancer

Russian Federation
Prestige Biopharma Limited

Active, not recruiting

A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Lung Cancer | Non-small Cell Lung Cancer

India, Hungary, Georgia, Philippines, Belarus, Bulgaria, Croatia, Greece, Latvia, Malaysia, Poland, Russian Federation, Serbia, Slovakia, Thailand, Turkey, Ukraine
CytRx

Terminated

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion

United States, Mexico, India, Ukraine, Bulgaria, Russian Federation
Synta Pharmaceuticals Corp.

Terminated

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer (GALAXY)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV

United States, Belgium, Bosnia and Herzegovina, Canada, Croatia, Czech Republic, Germany, Poland, Romania, Russian Federation, Serbia, Spain, United Kingdom
AstraZeneca

Active, not recruiting

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN)

Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, Belgium, Poland, Taiwan, Thailand, Korea, Republic of, Russian Federation, Austria
R-Pharm

Completed

A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

Advanced/Metastatic Non-Small Cell Lung Cancer

Germany, Korea, Republic of, Russian Federation, Taiwan, Australia, Italy, France, United States, Argentina, Spain
Novartis Pharmaceuticals

Terminated

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N)

Non-small Cell Lung Cancer

Canada, Netherlands, Spain, France, Japan, Russian Federation, Germany, Belgium, Greece, Turkey, Taiwan, United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Poland, Germany, Russian Federation, Latvia, Ukraine
NewLink Genetics Corporation

Completed

A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Russian Federation, Ukraine
Pharmacyclics LLC.

Terminated

Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)

Lung Cancer

United States, Canada, Russian Federation, Serbia
Shanghai Henlius Biotech

Active, not recruiting

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Extensive Stage Small Cell Lung Cancer

China, Georgia, Poland, Russian Federation, Turkey, Ukraine
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
GlaxoSmithKline

Terminated

Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery

Lung Cancer, Non-Small Cell

United States, France, Germany, Russian Federation, Poland, Italy
Sanofi

Completed

Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer (DISRUPT)

Non-small Cell Lung Cancer

France, Romania, Poland, Croatia, Korea, Republic of, Italy, Chile, United States, Australia, Germany, Russian Federation, Serbia, Ukraine
Biocad

Recruiting

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC (DOMAJOR)

Non-Squamous Non-Small Cell Neoplasm of Lung

Czechia, Romania, Georgia, Hungary, Russian Federation, Slovakia
AstraZeneca
Parexel

Withdrawn

T790M Mutation Positive 2nd Line STandard of cAre Registry (T-STAR)

Non Small Cell Lung Cancer

Italy, Russian Federation, Spain, China, Netherlands, United States, Taiwan, France, Germany
AstraZeneca

Active, not recruiting

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Non Small Cell Lung Carcinoma NSCLC

Poland, Taiwan, Thailand, Vietnam, United States, Korea, Republic of, Hungary, Russian Federation, Turkey, China, Australia, Netherlands

Clinical Trials on Carcinoma, Non-Small-Cell Lung in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations